009420 — Hanall Biopharma Share News
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩155bn
MacroGenics rises after FDA nod for rare skin cancer therapy
Nurix gains as Gilead to license protein degradation drug candidate
Abeona up on clinical development plans for eye diseases therapies
Brief: Hanall Biopharma's Licensed Partner In China Announces Phase 3 Results For Batoclimab In Myasthenia Gravis
Travere Therapeutics soars as kidney disorder drug bags FDA approval
Travere Therapeutics rises as kidney disorder drug bags FDA approval
Pharming falls as leniolisib's review loses accelerated tag in Europe
Concert Pharma rises as hairloss drug keeps breakthrough therapy tag
Brief: HanAll Biopharma Invests In Interon To Seek Collaboration Opportunities
Brief: Hanall Biopharma Says Top-Line Data From Tanfanercept's Phase 3 Expected In H1 2023
H.C. Wainwright doubtful of Intercept Pharma's NASH drug getting FDA approval
Intercept Pharma gains on resubmitting NASH drug for FDA review
Verona surges as lung disease therapy meets main goal in late-stage study
Ligand Pharmaceuticals down as CEO John Higgins retires
SVB starts Alpine Immune with 'outperform'
Cullinan Oncology shares get 'buy' rating as BTIG starts coverage
Brief: Hanall Biopharma Reports Third Quarter 2022 Results
Wedbush bullish on Imago Bioscience's lead drug potential; shares gain
Brief: Hanall Biopharma Q3 Operating Profit 1.1 Billion Won, Down 45% From Year Earlier